Published in Clin Exp Immunol on July 01, 1999
T cell help is required to induce idiotypic-anti-idiotypic autoantibody network after immunization with complementary epitope 289-308aa of La/SSB autoantigen in non-autoimmune mice. Clin Exp Immunol (2004) 0.79
Significant changes in the levels of secreted cytokines in brains of experimental antiphospholipid syndrome mice. Autoimmune Dis (2012) 0.76
Innate and humoral recognition of the products of cell death: differential antigenicity and immunogenicity in lupus. Clin Exp Immunol (2016) 0.75
The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today (1996) 12.12
Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med (1993) 4.99
T helper cell subsets in insulin-dependent diabetes. Science (1995) 3.92
On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol (1983) 3.57
In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med (1987) 2.93
Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med (1994) 2.71
TH2 cells in systemic autoimmunity: insights from allogeneic diseases and chemically-induced autoimmunity. Immunol Today (1991) 2.06
Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.03
Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A (1991) 1.77
Detection of individual mouse splenic T cells producing IFN-gamma and IL-5 using the enzyme-linked immunospot (ELISPOT) assay. J Immunol Methods (1990) 1.74
Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA. J Immunol (1984) 1.61
Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum (1996) 1.61
The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today (1995) 1.51
Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest (1992) 1.39
Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol (1990) 1.33
Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metab (1993) 1.23
Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Eur J Immunol (1995) 1.11
Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol (1995) 1.11
High levels of TH2 cytokine gene expression in systemic lupus erythematosus. Rev Invest Clin (1996) 1.06
Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J (1994) 1.03
Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease. J Immunol (1997) 1.01
Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies. J Immunol (1993) 0.94
Complexities in the treatment of autoimmune disease. Science (1996) 0.92
The putative role of cytokines in the induction of primary anti-phospholipid syndrome in mice. Clin Exp Immunol (1992) 0.91
Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest (1993) 0.90
Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol (1995) 0.89
Down-regulation of collagen arthritis after in vivo treatment with a syngeneic monoclonal anti-idiotypic antibody to a cross-reactive idiotope on collagen II auto-antibodies. Immunology (1991) 0.88
The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome. Am J Reprod Immunol (1993) 0.86
Induction of experimental anti-phospholipid syndrome associated with SLE following immunization with human monoclonal pathogenic anti-DNA idiotype. J Autoimmun (1992) 0.85
A common anti-cardiolipin antibody idiotype in autoimmune disease: identification using a mouse monoclonal antibody directed against a naturally-occurring anti-phospholipid antibody. Clin Exp Immunol (1989) 0.85
Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies. J Rheumatol (1994) 0.85
Immunoglobulins and the regulation of autoimmunity through the immune network. Clin Exp Rheumatol (1996) 0.84
The H3 anti-phospholipid idiotype is found in patients with systemic lupus erythematosus (SLE) but not in patients with syphilis. Clin Exp Immunol (1991) 0.83
Anti-idiotype as a probe in the analysis of autoimmune tubulointerstitial nephritis in the Brown Norway rat. J Immunol (1983) 0.83
Modulation of SLE induction in naive mice by specific T cells with suppressor activity to pathogenic anti-DNA idiotype. Cell Immunol (1991) 0.83
Gold and D-penicillamine induce vasculitis and up-regulate mRNA for IL-4 in the Brown Norway rat: support for a role for Th2 cell activity. Clin Exp Immunol (1997) 0.81
Suppression of experimental antiphospholipid syndrome and systemic lupus erythematosus in mice by anti-CD4 monoclonal antibodies. Arthritis Rheum (1994) 0.80
Induction of phospholipid-binding antibodies in mice and rabbits by immunization with human beta 2 glycoprotein 1 or anticardiolipin antibodies alone. Clin Exp Immunol (1993) 0.79
Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells. Cell Immunol (1995) 0.78
Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular-weight heparin. Am J Obstet Gynecol (1993) 0.78
Experimental autoimmune uveoretinitis: idiotypic regulation and disease suppression. Int Ophthalmol (1990) 0.78
Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate. Clin Exp Immunol (1994) 0.78
Induction of tolerance to experimental anti-phospholipid syndrome (APS) by syngeneic bone marrow cell transplantation. Scand J Immunol (1995) 0.77
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost (2006) 16.11
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum (1999) 7.67
Polyspecificity of monoclonal lupus autoantibodies produced by human-human hybridomas. N Engl J Med (1983) 4.43
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus (2003) 3.61
Editorial: The First Specialist Qualification Examination of the Japanese Society of Intravascular Neurosurgery (JSIN). Interv Neuroradiol (2004) 3.03
Idiotypic cross-reactions of monoclonal human lupus autoantibodies. J Exp Med (1983) 2.96
Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet (1990) 2.87
Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol (1996) 2.83
Rheumatology in Israel. Br J Rheumatol (1996) 2.66
Serum antibodies in epilepsy and seizure-associated disorders. Neurology (2005) 2.53
Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol (1984) 2.43
Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet (1998) 2.31
Production of autoantibodies by human-human hybridomas. J Clin Invest (1982) 2.22
Crossed aphasia elicited by direct cortical stimulation. Neurology (2006) 2.15
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis (2010) 2.09
Characterization of biologically active antineutrophil cytoplasmic antibodies induced in mice. Pathogenetic role in experimental vasculitis. Arthritis Rheum (1995) 2.09
Anti-DNA antibody idiotypes in systemic lupus erythematosus. Lancet (1984) 2.08
Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut (2000) 2.06
Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene (1995) 2.05
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis (2010) 2.04
Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) (2001) 2.02
Basophil infiltration in eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia. Aliment Pharmacol Ther (2015) 2.01
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis (2007) 2.01
Specificity of mouse hybridoma antibodies to DNA. Immunol Lett (1982) 1.93
Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation (1996) 1.92
Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci U S A (1988) 1.91
Antibodies cross-reactive with DNA and cardiolipin in patients with systemic lupus erythematosus. Clin Exp Immunol (1982) 1.90
Hematoma enlargement in spontaneous intracerebral hemorrhage. J Neurosurg (1994) 1.87
Colchicine treatment for recurrent pericarditis. A decade of experience. Circulation (1998) 1.87
Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes (1987) 1.86
Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum (1996) 1.78
Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A (1991) 1.77
Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol (1996) 1.76
Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clin Immunol Immunopathol (1984) 1.76
Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med (1994) 1.74
Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut (2005) 1.73
An ATP-based method for monitoring the microbiological drinking water quality in a distribution network. Water Res (2003) 1.71
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
Natural history of intracranial cavernous malformations. J Neurosurg (1995) 1.64
Mediastinal lymph node metastasis in patients with clinical stage I peripheral non-small-cell lung cancer. J Thorac Cardiovasc Surg (1997) 1.59
No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J Rheumatol (1996) 1.58
Unilateral adrenalectomy improves insulin resistance and polycystic ovaries in a middle-aged woman with virilizing adrenocortical adenoma complicated with Cushing's syndrome. J Endocrinol Invest (2007) 1.57
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis (2001) 1.55
Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus. Arthritis Rheum (1984) 1.53
Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis (2004) 1.53
Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis (2010) 1.52
Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus (2005) 1.51
Diagnostic value of DNA analysis in effusions by flow cytometry and image analysis. A prospective study on 102 patients as compared with cytologic examination. Am J Clin Pathol (1991) 1.50
Immunologic and genetic factors in autoimmune diseases. N Engl J Med (1984) 1.50
Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol (1998) 1.49
Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology (1999) 1.49
Elevated homocysteine levels in patients with Raynaud's syndrome. J Rheumatol (1999) 1.49
IgA class anti-beta2-glycoprotein I in patients with systemic lupus erythematosus. J Rheumatol (1998) 1.49
The prevalence of coeliac disease antibodies in patients with the antiphospholipid syndrome. Lupus (2003) 1.48
Novel biomarkers of acute kidney toxicity. Clin Pharmacol Ther (2009) 1.48
Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis (2003) 1.48
Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford) (2008) 1.48
Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum (1985) 1.48
Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity. Ann Rheum Dis (2005) 1.48
Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol (1992) 1.47
Anticardiolipin antibodies in Japanese patients with multiple sclerosis. Acta Neurol Scand (1993) 1.47
Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant (1998) 1.47
Advanced glycation endproducts and diabetic nephropathy. J Diabetes Complications (1996) 1.47
Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum (1997) 1.45
Autoantibodies in neoplasia. An unresolved enigma. Cancer (1990) 1.45
Role of beta 2-glycoprotein I in the antiphospholipid antibody binding to endothelial cells. Lupus (1995) 1.44
Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis (2005) 1.44
The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome--molecular mimicry? J Rheumatol (2000) 1.44
Ultra-early rebleeding in spontaneous subarachnoid hemorrhage. J Neurosurg (1996) 1.44
Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation. The importance of the T cell. Arthritis Rheum (1995) 1.44
Haemophagocytic syndrome in a patient with dermatomyositis. Br J Rheumatol (1998) 1.43
The good, the bad and the ugly of vaccination. Isr Med Assoc J (2000) 1.43
Clinical characteristics of ruptured chordae tendineae in hospitalized patients: primary tear versus infective endocarditis. Clin Cardiol (1998) 1.42
The cadherin-like protein is essential to specificity determination and cytotoxic action of the Bacillus thuringiensis insecticidal CryIAa toxin. FEBS Lett (1999) 1.42
Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med (2000) 1.42
A multidimensional autoantibody analysis specifying systemic lupus erythematosus patients with neuropsychiatric symptomatology. Isr J Med Sci (1992) 1.41
Plasma tumor necrosis factor alpha levels and the -238*A promoter polymorphism in patients with antiphospholipid syndrome. Thromb Haemost (2001) 1.41
Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction. Isr J Med Sci (1996) 1.40
Presence of a 16/6 related human anti-DNA common idiotype (SA1) in the anticardiolipin antibodies of patients with primary antiphospholipid syndrome. J Rheumatol (1991) 1.40
Superior vena cava occlusion in a patient with antiphospholipid antibody syndrome. J Rheumatol (1991) 1.40
Effect of beta 2glycoprotein I and human monoclonal anticardiolipin antibody on the protein S/C4b-binding protein system. Lupus (1997) 1.40
A clinicopathological study of dissecting aneurysms of the intracranial vertebral artery. J Neurosurg (1991) 1.40
Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest (1992) 1.39
Use of the SpaceMaker balloon in sternal wound closure: comparison with other techniques. Plast Reconstr Surg (2001) 1.39
Antiphospholipid antibody testing - slow progress? Int J Clin Pract (2012) 1.39
Granular lymphocyte proliferative disorder after autologous peripheral blood stem cell transplantation for multiple myeloma. Eur J Haematol (2003) 1.39
Stress platelets in normal individuals and patients with idiopathic thrombocytopenic purpura. Blood Cells (1992) 1.39
Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun (2000) 1.38
Screening for prostate cancer. Isr J Med Sci (1995) 1.38
[Viagra--the first oral treatment for impotence that is not lacking in fatal effects]. Harefuah (1998) 1.38